|163.00||+2.56||+1.60%||Vol 8.09M||1Y Perf 12.03%|
|Feb 24th, 2021 15:56 DELAYED|
|1.96 1.22%||- -|
|Target Price||183.08||Analyst Rating||Moderate Buy 1.56|
|Potential %||12.10||Finscreener Ranking||★★+ 48.29|
|Insiders Trans % 3/6/12 mo.||-100/-100/-60||Value Ranking||★★+ 50.36|
|Insiders Value % 3/6/12 mo.||-100/-100/-99||Growth Ranking||★★★★+ 63.32|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-99||Income Ranking||★★★ 46.04|
|Market Cap||429.10B||Earnings Rating||Buy|
|Price Range Ratio 52W %||83.49||Earnings Date||13th Apr 2021|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||13th Apr 2021|
|Estimated EPS Next Report||2.30|
|EPS Growth Next 5 Years %||7.70|
|Avg. Weekly Volume||6.75M|
|Avg. Monthly Volume||8.29M|
|Avg. Quarterly Volume||8.03M|
Johnson & Johnson (NYSE: JNJ) stock closed at 160.44 per share at the end of the most recent trading day (a -0.88% change compared to the prior day closing price) with a volume of 7.04M shares and market capitalization of 428.76B. Is a component of S&P 500, Dow Jones 30, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 135100 people. Johnson & Johnson CEO is Alex Gorsky.
The one-year performance of Johnson & Johnson stock is 12.03%, while year-to-date (YTD) performance is 1.94%. JNJ stock has a five-year performance of 52.86%. Its 52-week range is between 109.16 and 173.65, which gives JNJ stock a 52-week price range ratio of 83.28%
Johnson & Johnson currently has a PE ratio of 30.10, a price-to-book (PB) ratio of 6.77, a price-to-sale (PS) ratio of 5.16, a price to cashflow ratio of 20.50, a PEG ratio of 2.32, a ROA of 8.66%, a ROC of 17.93% and a ROE of 22.97%. The company’s profit margin is 18.01%, its EBITDA margin is 32.60%, and its revenue ttm is $82.58 Billion , which makes it $31.37 revenue per share.
Of the last four earnings reports from Johnson & Johnson, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.30 for the next earnings report. Johnson & Johnson’s next earnings report date is 13th Apr 2021.
The consensus rating of Wall Street analysts for Johnson & Johnson is Moderate Buy (1.56), with a target price of $183.08, which is +12.10% compared to the current price. The earnings rating for Johnson & Johnson stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Johnson & Johnson has a dividend yield of 2.50% with a dividend per share of $4.04 and a payout ratio of 61.00%.
Johnson & Johnson has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.30, ATR14 : 4.19, CCI20 : -107.93, Chaikin Money Flow : -0.23, MACD : 0.73, Money Flow Index : 48.03, ROC : -2.44, RSI : 43.44, STOCH (14,3) : 10.39, STOCH RSI : 0.00, UO : 46.16, Williams %R : -89.61), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Johnson & Johnson in the last 12-months were: Ashley McEvoy (Sold 29 000 shares of value $4 276 630 ), Kathryn E. Wengel (Option Excercise at a value of $1 027 323), Kathryn E. Wengel (Sold 16 115 shares of value $2 473 937 ), Michael E. Sneed (Option Excercise at a value of $3 399 976), Michael E. Sneed (Sold 54 662 shares of value $8 359 459 ), William D. Perez (Buy at a value of $63 843)
Copyright (c) 2021. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.